Product Description
Gage Development Company is developing GDC-695 as a treatment for actinic keratosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02952898)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Balmoral Medical company
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Keratosis, Actinic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GDC-695-001 | P3 |
Completed |
Keratosis, Actinic |
2017-07-11 |
46% |